IMNN IMNN
Company Profile ↓Company Overview
IMNN (IMNN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +0.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.00% |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | -80.12% |
| 6 Months: | -50.00% |
| 3 Months: | -42.60% |
| 1 Month: | -18.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.57 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 80.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 125.00K | - | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | 125.00K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -3.53M | -5.20M | -6.41M | -6.67M | - | -6.41M | -5.24M | -4.24M | - | -5.18M | -4.74M | -5.60M | -4.82M | -4.40M | -4.40M | -4.28M | -8.01M | -4.02M | -4.86M | -5.57M | -5.39M | -4.77M | -4.77M | -4.16M | -5.38M | -5.07M | -5.06M | -5.84M | -5.98M | -6.17M | -5.68M | -5.47M | -3.90M | -5.01M | -5.01M | -4.96M | -4.15M | -2.77M | -3.48M | -4.31M |
| Net Income | -4.07M | -5.42M | -6.67M | -6.94M | -6.46M | -7.01M | -5.67M | -4.27M | -5.51M | -5.72M | -4.53M | -6.41M | -5.16M | -5.67M | -5.67M | -4.48M | -8.23M | -4.66M | -2.37M | -5.90M | -5.48M | -5.06M | -5.34M | -8.07M | -5.69M | -5.45M | -5.41M | -10.47M | -6.04M | -6.15M | -5.59M | -5.56M | -3.48M | -4.93M | -4.79M | -4.85M | -4.10M | -2.74M | -3.43M | -4.25M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.87 | -0.87 | -0.68 | -0.61 | -0.37 | -0.52 | -7.64 | -3.76 | -3.15 | -2.15 | -1.16 | -0.84 |
| R&D Expense | 2.27M | 2.89M | 3.17M | 4.63M | - | 4.51M | 3.57M | 2.88M | - | 3.44M | 3.34M | 4.23M | 3.48M | 3.35M | 3.35M | 2.74M | 4.59M | 2.19M | 2.77M | 3.56M | 3.67M | 3.05M | 2.99M | 2.49M | 2.57M | 2.59M | 2.47M | 3.10M | 3.23M | 2.41M | 2.62M | 3.13M | 1.98M | 3.29M | 2.82M | 3.29M | 2.17M | 1.23M | 1.90M | 2.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | - | - | - |
| Operating Income | -19.64M | -23.02M | -22.14M | -15.41M | -24.72M | -20.85M | -20.65M | -18.47M | -21.07M | -20.57M | -18.49M | -21.01M | -24.92M | -21.03M | -19.13M | -14.65M |
| Net Income | -18.82M | -23.22M | -26.57M | -8.25M | -25.49M | -22.46M | -22.05M | -20.40M | -11.88M | -16.85M | -21.48M | -20.77M | -35.90M | -19.51M | -18.62M | -14.50M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -5.03 | -2.16 | -16.94 | -6.83 |
| R&D Expense | 14.71M | 19.86M | 15.77M | 9.36M | 14.97M | 14.66M | 14.62M | 13.08M | 11.87M | 13.07M | 11.34M | 10.62M | 11.73M | 11.29M | 11.64M | 7.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Sep 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.53M | 32.65M | 25.36M | 45.67M | 66.69M | 49.03M | 30.85M | 47.51M | 46.86M | 38.28M | 37.53M | - | 74.05M | 43.98M | 21.92M | 9.72M | 12.29M |
| Total Equity | 10.04M | -4.58M | 26.19M | 11.96M | 31.52M | 32.83M | 20.39M | 6.73M | 26.70M | 20.86M | 14.56M | 18.61M | - | 55.80M | 29.33M | 13.39M | 4.24M | 7.06M |
| Cash & Equivalents | 6.92M | 1.14M | 20.15M | 14.99M | 5.72M | 12.69M | 9.27M | 2.62M | 11.44M | 13.35M | 6.88M | 17.16M | - | 19.59M | 11.49M | 5.84M | 5.87M | 8.78M |
| Long Term Debt | - | - | - | 5.00M | 5.00M | - | - | - | - | 9.42M | 9.80M | 5.05M | 5.85M | - | 5.96M | - | - | - |
| Total Liabilities | - | 7.10M | 6.46M | 13.40M | 14.15M | 33.87M | 28.64M | 24.12M | 20.81M | 25.99M | 23.72M | 18.92M | - | 18.25M | 14.65M | 8.53M | 5.47M | 5.23M |
| Current Liabilities | - | 6.80M | 6.15M | 5.01M | 4.67M | 10.09M | 9.32M | 8.42M | 6.20M | 6.11M | 7.89M | 6.75M | - | 6.77M | 10.04M | 7.39M | 4.79M | 4.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.37M | -22.74M | -22.14M | -9.53M | -21.35M | -20.83M | -18.38M | -16.64M | -7.04M | -20.26M | -15.62M | -16.22M | -23.10M | -19.02M | -18.85M | -13.90M |
| Investing Cash Flow | 5.21M | -11.09M | 1.47M | -29.14M | 9.54M | 13.33M | 9.06M | -10.99M | -1.63M | 5.94M | 7.92M | -30.12M | 8.28M | 11.01M | 9.83M | -280.57K |
| Financing Cash Flow | 2.38M | 52.84M | 15.52M | 29.39M | 18.78M | 4.08M | 2.68M | 36.45M | 10.58M | 7.84M | 17.98M | 54.77M | 6.72M | -3.64M | 9.06M | 17.09M |
| Capital Expenditure | -6.75K | -573.41K | -613.39K | -57.49K | -672.26K | -109.34K | -62.50K | -38.63K | -138.40K | -349.16K | -19.09K | -311.61K | -267.80K | -451.76K | -29.54K | -280.57K |
| Free Cash Flow | -13.37M | -23.32M | -22.76M | -9.58M | -22.03M | -20.94M | -18.44M | -16.68M | -7.18M | -20.61M | -15.64M | -16.54M | -23.36M | -19.47M | -18.88M | -14.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -3,693.7% | -4,213.0% | -4,113.1% | -3,697.3% | -4,201.4% | -4,984.3% | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | -4,080.4% | -2,376.7% | -3,370.3% | -4,296.7% | -4,153.9% | -7,179.6% | - | - | - |
| ROE % | 411.3% | -88.7% | -222.1% | -26.2% | -77.7% | -110.2% | -327.9% | -76.4% | -57.0% | -115.7% | -115.4% | -37.2% | -122.4% | -145.8% | -438.7% | -205.3% |
| ROCE % | 459.8% | -86.9% | -108.8% | -37.6% | -43.7% | -52.5% | -92.1% | -44.7% | -51.7% | -67.7% | -60.1% | -31.2% | -73.4% | -144.8% | -388.0% | -191.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMNN
IMUNON Plans Phase 3 Ovarian Cancer Update on Aug. 11 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPNTBYMjkzZ2tBbVlHckhRMjhJb3lMcW5PSVR0cHdYS1B4OWgzNlFHTlVpVk03SnpJb19mNDZzTUZ3WlFJUlpaSVBQYnZnMWxHU1FPSDVqZzVjSW8tZ19rZFRtcm9feFd3WEZBQ3FVZUd0UTJxdDRtc2lLTlpvbW0wcHJsdGxSUEoyaE43Rk…
Imunon (IMNN) director granted 6,934 shares of stock for board fees - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOdldUNmxheEx2RDBWYVhHSmdnN2VOaEM3ajFaZ2plRFhOVWtSTFZYOS1ZMGxyY0lNM1ZtdzBLMWRqdVZDQ2VJQWI0aWdpQlhUTTgwaUM5c1RVNkJIaUxnYndUVjNPYU9QSTlGZmFZOWhjVU5tUVlNSm9ta092VG5naWhpUFMtUUY2MGdVc1…
IMUNON Reports Faster-Than-Expected Enrollment in Phase 3 OVATION 3 Trial of IMNN-001 for Advanced Ovarian Cancer - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPZEFMZ25XdHZDSThzWWpwNEV2S0R0a2F5SkpSOEd2czZJUDlJaWxPMVBKZDJBQ1J1UmhHYXVnbmVQN0NnNmhXX3JZWTB0aFd3SHc1cVhsMmJidWlVblNoRFlabVlxeUlVS1lnTnd3ZFByYUNTdy13NERJR3pVS3BrR0FveHFCN05QODFuOD…
IMNN|Imunon Inc|Price:1.670|Chg%:+0.090 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBjX0lOaG9LTV9jUE0yRWE3Z1BFdjdSa1E5YjZVXzFZYUJVb3BxeUdDTmdQel80aHBBSW8tbkY5NFp4T2JFX21ZY1NjM01QSWllbVpyVEptMlpwdlZvOXFKRFFNblplcWVyb1gzZmJn?oc=5" target="_blank">IMNN|Imunon Inc|Pri…
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study - Sahm
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOMHViY0wtN243MEw5TXAxMXBPVlhoMjRBZHJHckZuc3RJSmZjU3JoOXQwOWxtSm9ZX1NZMm9RYUdiYktjYlR2OWJrX0xRVUFaSnFqSktoRk5GRU1ic0ZGNm9TRDQ5Z0ZSRWlPWFJnZllISDZIWkgtTnhEbWFGZUduRTlVbHdva0pMOW9Jc0…
Imunon, Inc. Revenue Breakdown – NASDAQ:IMNN - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9kSWo1djlITEpPZWdRWG9IX3ROOGxyRXZXMk4zSEotMGN1R3d2M19mRVBGV0IzeE1tMDg2RFh2RlEwbHZBMmVPbTdybnlnTjZud0lyYnBCS2FuQVF0WGRmYUdob1p4RENkLWh5cFJVYTRxdnRqU3NR?oc=5" target="_blank">Imunon,…
IMNN — Frequently Asked Questions
What is the current share price of IMNN?
As of 2026-08-05 17:25 PDT, IMNN trades at $1.59 on NASDAQ/NYSE. Its 52-week range is $1.51 to $8.00.
What is the P/E ratio of IMNN?
IMNN trades at a trailing price-to-earnings (P/E) ratio of -0.23.
Is IMNN a good stock to buy?
This page provides a data-driven analysis of IMNN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.